Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a ...
Femasys Inc. announced the achievement of CE mark certification for the FemBloc delivery system, marking it as the first regulatory approval in the world for a non-surgical permanent birth control ...
Researchers have demonstrated that a single dose of anti-Müllerian hormone (AMH) gene therapy can induce long-term contraception in the domestic cat, potentially providing a safe and effective ...
Birth control or contraception is important for adults of all ages. However, choosing the right method of birth control is just as important for people over the age of 40. As women get older, their ...
--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- Jordi Escorihuela, Chief Executive Officer of Comercial Medico Quirúrgica, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback